Age-related differences in patient burden in endometrial cancer: Findings from the international EXPRESSION XI/IMPROVE survey.
Abstract
e17622 Background: Despite favourable survival in early-stage endometrial cancer (EC), patients experience a substantial disease- and treatment-related burden that negatively affect quality of life (QoL). The aim was to compare the most burdensome problems reported by patients with EC in different age groups. Methods: This international, anonymous survey was conducted within NOGGO, GCIG, ENGOT and ENGAGe. The 80-item questionnaire covered demographics, medical history, current symptoms, lifestyle, and self-perception. Eligible participants had a history of EC, regardless of stage or treatment. Four age-based subgroups were defined: (A) <40 years, (B) 40-70 years, (C) 71-80 years, and (D) >80 years. Analyses were descriptive and exploratory. Results: Overall, 2,761 women from 20 countries completed the survey. Of these, 36 were in subgroup A, 1,105 in subgroup B, 162 in subgroup C, and 162 in subgroup D. Treatment-related side effects were largely similar across age groups, though differences were observed in hair loss, exhaustion, pain, concentration, and lymphedema. Hair loss affected 34% of patients in group C, compared to only 18% in group D. In group A, almost 40% were affected by exhaustion, whereas only 24% of group D reported exhaustion. Pain was most prevalent in group A, at 25%, while in group D it was 13%. Concentration problems were reported by 22% of group A and only 15% of group D. Group A was also most affected by lymphedema, with 19% compared to 13% in group D. With regard to the problems of the past week, it was clear that patients in A reported significantly more worries (69% vs. 50 % (B) vs. 38 % (C) vs. 29% (D)), fears (56% vs. 44 % (B) vs. 25 % (C) vs. 20% (D)), sadness (53% vs. 33 % (B) vs. 23 % (C) vs. 18% (D)), and depression (22% vs. 14 % (B) vs. 9 % (C) vs. 7% (D)). Younger patients were also more concerned about their appearance (36% vs. 9 % (B) vs. 7 % (C) vs. 5% (D)). In contrast, more patients in group C and D complained of neuropathies (33% (C) and 30% (D) vs. 17 % (A) vs. 27 % (B)). Nausea, pain, sleep problems, nervousness, inflammation in the mouth area, obstipation, diarrhea, fever, and dry skin were equally distributed across all age groups. Conclusions: Treatment- and disease-related symptoms are common in endometrial cancer survivors, with younger patients reporting more exhaustion, concentration problems, and emotional distress, while elderly patients experience more neuropathies. Age-specific differences should guide follow-up care to improve quality of life. Clinical trial information: DRKS00025954.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (20)
Pierre Combe
Medical Oncology Department, VIVALTO Santé, Pôle Santé Léonard de Vinci, Chambray-lès-tours, France
Lukas Chinczewski
North-Eastern German Society of Gynecological Oncology (NOGGO) & Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany
Martina Romanova
Gynecologic Oncology Center, Department of Gynecology and Obstetrics, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Tibor Zwimpfer
Swiss-GO & Gynaecological Cancer Centre, University Hospital Basel and Ovarian Cancer Research, University of Basel, Basel, Switzerland
Maria-Pilar Barretina-Ginesta
Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Medical Oncology Department, Institut Català d´Oncologia (ICO), Girona, Spain
Gerda Trutnovsky
Universitätsklinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz, 8010 Graz, Österreich and Arbeitsgemeinschaft Gynaekologische Onkologie Austria (AGO Austria), Innsbruck, Austria
Hannelore Denys
Ghent University Hospital, Department of Medical Oncology, Ghent, Belgium
Adelina Silvana Gheorghe
Aging and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain and Institutul Oncologic Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania
Sara Nasser
Pan-Arabian Research Society of Gynecological Oncology (PARSGO) and Department of Gynecology with Center for Oncological Surgery, Charité—Universitätsmedizin Berlin, Berlin, Germany
Jonathan S. Berek
Stanford Women’s Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
Clemens Liebrich
Klinikum Wolfsburg - Gynäkologisches Krebszentrum, Wolfsburg and Harzklinikum Dorothea Christiane Erxleben, Klinik für Frauenheilkunde und Geburtshilfe, Wernigerode, Wernigerode, Germany
Laurence Gladieff
Veronika Patsko
Department of Clinical Oncology, National Cancer Institute, Kyiv, Ukraine
Flurina Saner
Swiss-GO & University Hospital of Bern, Bern, Switzerland
Karol Kubiak
St. Franziskus Hospital, Münster, Germany
Laura Mansi
CHU de Besançon, Service d'Oncologie Médicale and GINECO, Besançon, France
Matthias Losch
Department of Gynecology with Cancer Center, Augusta Kliniken Bochum, Bochum, Germany
Icó Tóth
Mallow Flower Foundation, Hungary and ESGO ENGAGe, Brussels, Belgium
Luka Kovac
Department for Gynecology and Obstetrics, University Medical Centre Ljubljana, Ljubljana, Slovenia
Jalid Sehouli
Department of Gynecology Center of Oncological Surgery European Competence Center for Ovarian Cancer, Charité‐University Medicine Berlin Berlin Germany